Complications of β-thalassemia intermedia in Iran during 19962010 (Single-Center Study)

Pediatric Hematology and Oncology

Volumn 28, Issue 6, 2011, Pages 497-508

  Rafsanjani, Khadijeh Arjmandi ^a   Mafi, Negar ^a   Tafreshi, R Isa ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cholelithiasis; complications; endocrine disease; pulmonary hypertension; Splenectomy; Thalassemia intermedia; Thrombocytosis

Indexed keywords

FERRITIN; HEMOGLOBIN; LIVER ENZYME;

ADOLESCENT; ADRENAL INSUFFICIENCY; ARTICLE; BETA THALASSEMIA; BONE DENSITY; CEREBROVASCULAR ACCIDENT; CHOLELITHIASIS; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; INCIDENCE; IRAN; IRON CHELATION; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; OSTEOPOROSIS; PORTAL VEIN THROMBOSIS; PRACTICE GUIDELINE; PREVALENCE; PULMONARY HYPERTENSION; RISK FACTOR; SPLENECTOMY; THROMBOCYTOSIS; VIRUS HEPATITIS;

ADOLESCENT; ADULT; AGE FACTORS; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; CHOLELITHIASIS; CROSS-SECTIONAL STUDIES; ENDOCRINE SYSTEM DISEASES; FEMALE; HUMANS; HYPERTENSION, PULMONARY; IRAN; MALE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; RETROSPECTIVE STUDIES; SOFTWARE; SPLENECTOMY; THROMBOCYTOSIS;

EID: 80052001713     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2011.572144     Document Type: Article

References (32)

1. Sweelay T. β-Thalassaemia. Baillière Clin Haematol. 1998;11:91-126.
2. El Rassi F, Cappellini MD, Inati A, Taher A. Beta-thalassemia intermedia: an overview. Pediatr Ann. 2008;37:322-328. (Pubitemid 351847504)
3. World Health Organization Genomic Resource Centre. Resources for patients and the public, monogenic diseases: thalassemia. Available at: http://www.who.int/genomics/public/ geneticdiseases/en/index2.html. Accessed 1 January 2009.
4. Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47:792-800. (Pubitemid 46668992)
5. Thalassemia International Federation. Chapter 11: Thalassaemia Intermedia & HbE. In: Guidelines for the Clinical Management of Thalassemia. 2nd ed. Nicosia, Cyprus:Thalassaemia International Federation. 2007:121-133.
6. Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol. 2007;138:291-304. (Pubitemid 47035387)
7. Taher A, Ismaeel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis. 2006;27:12-20. (Pubitemid 44062361)
8. Inati A, Zeineh N, Ismaeel H, et al. β-Thalassemia: the Lebanese experience. Clin Lab Haematol. 2006;28:217-227.
9. Taher A, Ismaeel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96:488-491. (Pubitemid 44560684)
10. Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev. 2008;22:283-292.
11. Vogiatzi MG, Macklin EA, Fung EB, et al. Prevalence of fractures among the thalassemia syndromes in North America. Bone. 2006;38:571-575.
12. Aessopos A, Kati M, Farmakis D. Heart disease in thalassemia intermedia: a review of the underlying pathophysiology. Haematologica. 2007;92:658-665. (Pubitemid 350144268)
13. Nassar AH, Ihab M, Usta J, et al. Pregnancy in patients with β-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol. 2006;81:499-502.
14. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86:480-487. (Pubitemid 351821761)
15. Taher A, El Rassi F, Ismaeel H, Inati A. Complications of beta-thalassemia intermedia: a 12-year Lebanese experience. Am J Hematol. 2008;83:605-606. (Pubitemid 351874887)
16. Cappellini MD.The adult thalassemic patient. Hematol J. 2002:65-69.
17. Aessopos A, Farmakis D, Tsironi M, et al. Hemodynamic assessment of splenomegaly in β-thalassemia patients undergoing splenectomy. Ann Hematol. 2004;83:775-778. (Pubitemid 39485549)
18. Aessopos A, Farmakis D, Deftereos S, et al. Cardiovascular effects of splenomegaly and splenectomy in beta-thalassemia. Ann Hematol. 2005;84:353-357. (Pubitemid 40823347)
19. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: amulticenter study. Blood. 2001;97:3411-3416.
20. Aessopos A, Farmakis D, Deftereos S, et al.Thalassemia heart disease: a comparative evaluation of thalassemiamajor and thalassemia intermedia. Chest. 2005;127:1523-1530. (Pubitemid 46218775)
21. Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78:139-145. (Pubitemid 37021954)
22. Olivieri N.Thalassaemia: clinicalmanagement. Baillière Clin Haematol. 1998;147:147-162. (Pubitemid 29039021)
23. Olivieri NF. Brittenham GM Iron-chelating therapy and the treatment of thalassemia. Blood. 1997;89:739-761. (Pubitemid 27121266)
24. Papadimas J, Goulis DG, Mandala E, et al. Beta-thalassemia and gonadal axis: a cross-sectional, clinical study in a Greek population. Hormones (Athens). 2002;1:179-187.
25. Bhattacharyya M, Kannan M, Chaudhry VP, et al. Hypercoagulable state in five thalassemia intermedia patients. Clin Appl Thromb Hemost. 2007;13:422-427. (Pubitemid 350114516)
26. Dore F, Cianculli P, Rovasio S, et al. Incidence and clinical study of ectopic erythropoiesis in adult patients with thalassemia intermedia. Ann ItalMed Int. 1992;7:137-140.
27. Pignatti BC, Carnelli V, Caruso V, et al. Thromboembolic events in β-thalassemia major: an Italian multicentre study. Acta Haematol. 1998;99:76-79. (Pubitemid 28119099)
28. Mohamed N, Jackson N. Severe thalassemia intermedia: clinical problems in the absence of hypertransfusion review]. Blood Rev. 1998;12:163-170. (Pubitemid 28434427)
29. Shaw NJ. Management of osteoporosis in children. Eur J Endocrinol. 2008;159:S33-S39.
30. Domrongkitchaiporn S, Sirikulchayanonta V, Angchaisuksiri P, et al. Abnormalities in bone mineral density and bone histology in thalassemia. J BoneMineral Res. 2003;18:1682-1688. (Pubitemid 37022927)
31. Morabito N, Lasco A, Gaudio A, et al. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int. 2002;13:644-649.
32. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.